These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 30776080)

  • 1. Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report.
    Ressler J; Silmbrod R; Stepan A; Tuchmann F; Cicha A; Uyanik-Ünal K; Hoeller C
    Br J Dermatol; 2019 Jul; 181(1):186-189. PubMed ID: 30776080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.
    Burke EE; Zager JS
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.
    Fröhlich A; Niebel D; Fietz S; Egger E; Buchner A; Sirokay J; Landsberg J
    Cancer Immunol Immunother; 2020 May; 69(5):759-769. PubMed ID: 32052079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How We Do It: Administration Guide for Intralesional Immunotherapy With Talimogene Laherparepvec (T-VEC) for Advanced Melanoma.
    Queen D; Samie FH; Zeitouni NC
    Dermatol Surg; 2020 Nov; 46(11):1455-1457. PubMed ID: 31403542
    [No Abstract]   [Full Text] [Related]  

  • 5. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
    Gangi A; Zager JS
    Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model.
    Stahlie EHA; Franke V; Zuur CL; Klop WMC; van der Hiel B; Van de Wiel BA; Wouters MWJM; Schrage YM; van Houdt WJ; van Akkooi ACJ
    Cancer Immunol Immunother; 2021 Aug; 70(8):2291-2300. PubMed ID: 33507342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
    Afzal MZ; Shirai K
    J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
    Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
    Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
    Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
    J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrasound-guided Intralesional Injection of Talimogene laherparepvec (Imlygic) for Advanced Melanoma: Technical Note on a Preliminary Experience.
    Burke LMB; Yu H; Burke K; Gwynn M; Louie RJ; Ollila DW; Rn PL; Collichio F
    Cardiovasc Intervent Radiol; 2021 May; 44(5):801-806. PubMed ID: 33447922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions.
    Larocca CA; LeBoeuf NR; Silk AW; Kaufman HL
    Am J Clin Dermatol; 2020 Dec; 21(6):821-832. PubMed ID: 32767272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma.
    Schvartsman G; Perez K; Flynn JE; Myers JN; Tawbi H
    J Immunother Cancer; 2017; 5():45. PubMed ID: 28642816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
    Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
    Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a).
    Franke V; Berger DMS; Klop WMC; van der Hiel B; van de Wiel BA; Ter Meulen S; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
    Int J Cancer; 2019 Aug; 145(4):974-978. PubMed ID: 30694555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma.
    Haitz K; Khosravi H; Lin JY; Menge T; Nambudiri VE
    J Am Acad Dermatol; 2020 Jul; 83(1):189-196. PubMed ID: 32004650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.
    Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Treatment of In-Transit Metastatic Melanoma in a Renal Transplant Patient With Combination T-VEC/Imiquimod Immunotherapy.
    Sunshine JC; Sosman J; Shetty A; Choi JN
    J Immunother; 2020 May; 43(4):149-152. PubMed ID: 32235165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.
    Andtbacka RHI; Amatruda T; Nemunaitis J; Zager JS; Walker J; Chesney JA; Liu K; Hsu CP; Pickett CA; Mehnert JM
    EBioMedicine; 2019 Sep; 47():89-97. PubMed ID: 31409575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report.
    Chitnis SD; Seim NB; Kendra K
    J Med Case Rep; 2024 May; 18(1):257. PubMed ID: 38778387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.
    Mohr P; Haferkamp S; Pinter A; Weishaupt C; Huber MA; Downey G; Öhrling K; Loquai C; Louie KS
    Adv Ther; 2019 Jan; 36(1):101-117. PubMed ID: 30536143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.